The 25 references in paper I. Trofimenko N., B. Chernyak A., И. Трофименко Н., Б. Черняк А. (2014) “Бронхиальная гиперреактивность как фенотипическая характеристика хронической обструктивной болезни легких // Bronchial hyperresponsiveness as a phenotypic feature of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2011:i:4:p:49-53

1
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.
(check this in PDF content)
2
09. www.goldcopd.com 2.Agusti А., Calverley P.M.A., Celli B. et al.Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11 (1): 122.http://respiratory)research.com/content/ 11/1/122
(check this in PDF content)
3
Трофименко И.Н., Черняк Б.А. Взаимосвязь клиникофункционального статуса и качества жизни у больных хронической обструктивной болезнью легких. Сиб. консилиум 2008; 1 (64): 48–52.
(check this in PDF content)
4
Nishimura K., Izumi T., Tsukino M. et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–1440.
(check this in PDF content)
5
Gerardi D.A., Lovett L., Benoit)Connors M.L. et al. Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur. Respir. J. 1996; 9: 431–435.
(check this in PDF content)
6
Oga T., Nishimura K., Tsukino M. et al. Analysis of the Factors related to mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 544–549.
(check this in PDF content)
7
Casanova C., Cote C., de Torres J.P. et al. The inspiratory to total lung capacity ratio predicts mortality in patients with COPD. Am. J. Respir. Crit. Care Med. 2005; 171: 591–597. Таблица 3 Показатели спирометрии и 6;МШТ в зависимости от БГР ПараметрыMean ± SDр БГР+БГР– ОФВ1до бронходилататора, %долж.58,1 ± 8,460,5 ± 9,10,217 ОФВ1после бронхо- дилататора, %долж.65,6 ± 8,565,8 ± 7,20,698 ФЖЕЛ до бронходилататора, %долж.73,2 ± 18,080,0 ± 20,80,042 ФЖЕЛ после бронходилататора, %долж.86,7 ± 10,791,6 ± 13,50,338 6-МШТ, м470,4 ± 62,6475,7 ± 70,40,772 Одышка Борга, баллы3,7 ± 1,22,6 ± 0,80,002 Рис. 2. Показатели КЖ в зависимости от результатов метахолинового теста Примечание: * – р< 0,01.
(check this in PDF content)
8
Hospers J.J., Postma D.S., Rijcken B. et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356: 1313–1317.
(check this in PDF content)
9
Schols A.M., Slangen J., Volovics L., Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1791–1797.
(check this in PDF content)
10
Agust A., Noguera A., Sauleda J. et al.Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 347–360.
(check this in PDF content)
11
Wouters E.F.COPD: from an organ- to a disease-oriented approach. COPD 2008; 5 (2): 73–74.
(check this in PDF content)
12
Agusti A. COPD, a multicomponent disease: implications for management. Respir. Med. 2005; 99: 670–682.
(check this in PDF content)
13
Burgel P. R., Paillasseur J.L., Caillaud D. et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur. Respir. J. 2010; 36: 531–539.
(check this in PDF content)
14
Han M.K., Agusti A., Calverley P.M. et al.COPD phenotypes: The future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598–604.
(check this in PDF content)
15
Авдеев С.Н.Фенотипы хронической обструктивной болезни легких: особенности терапии. Consilium medicum 2010; прилож.: 23–28.
(check this in PDF content)
16
Garsia)Aymerich J., Agusti A., Barbera J.A. et al. Phenotypic heterogenetiy of chronic obstructive pulmonary disease. Arch. Broncopneumol. 2009; 45: 133–142.
(check this in PDF content)
17
Gulsvik A., Refvem O.K.Ascoring system on respiratory symptoms. Eur. Respir. J. 1988; 1: 428–432.
(check this in PDF content)
18
Чучалин А.Г. (ред.). Стандартизация легочных функциональных тестов. Пер. с англ. М.; 1993.
(check this in PDF content)
19
Kanner R.E., Connett J.E., Altose M.D. et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am. J. Respir. Crit. Care Med. 1994; 150 (4): 956–961.
(check this in PDF content)
20
Brutsche M.H., Downs S.H., Schindler C. et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA Cohort Study. Thorax 2006; 61: 671–677.
(check this in PDF content)
21
Grootendorst D.C., Rabe K.F.Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2004; 1: 77–87.
(check this in PDF content)
22
Khaodhiar L., Ling P.R., Blackburn G.L. et al. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. J. Parenter. Enter. Nutr. 2004; 28 (6): 410–415.
(check this in PDF content)
23
Bahceci M., Gokalp D., Bahceci S. et al.The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? J. Endocrinol. Invest. 2007; 30 (3): 210–214.
(check this in PDF content)
24
Xu X., Rijcken B., Schouten J.P. et al.Airways responsiveness and development and remission of chronic respiratory symptoms in adults. Lancet 1997; 350: 1431–1434.
(check this in PDF content)
25
Leuppi J.D., Tandjung R., Anderson S.D. et al. Prediction of treatment-response to inhaled corticosteroids by mannitolchallenge test in COPD. A proof of concept. Pulm. Pharmacol. Ther. 2005; 18 (2): 83–88. Информация об авторах
(check this in PDF content)